Investigation of rituximab for candidate of high-risk living-donor renal transplantation

Investigation of rituximab for candidate of high-risk living-donor renal transplantation - Investigation of rituximab for candidate of high-risk living-donor renal transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018769

Enrollment

Registered

2015-08-24

Start date

2014-09-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage chronic renal failure

Interventions

administration of rituximab before/after living-donor renal transplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) ABO minor mismach 2) ABO incompatible 3) with anti donor antibody 4) renal failure due to FSGS 5) antibody mediated rejection 6) relapsing nephropathy

Exclusion criteria

Exclusion criteria: 1) excluding 1)-4), 6) (see above) 2) impertinent recipient for this study assessed by main/co-scholar 3) without concensus of recipient

Design outcomes

Primary

Measure	Time frame
1) disappearance of B cell 2) existence of antibody mediated rejection 3) relapse of FSGS 4) effectiveness for rejection 5) effectiveness for relapsing nephropathy	—

Countries

Japan

Contacts

Public ContactShingo Nishimura

Okayama University Hospital Department of Urology

shingo0414@gmail.com086-235-7287

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026